An international team led by a physician from the Karl Landsteiner University for Health Sciences, Krems, describes for the first time a mutation of the IL-33 gene in the human genome that results in multiple allergic disease ...
May 27, 2022
0
314
SARS-CoV-2, the virus that causes COVID-19, has continuously mutated since it emerged in late 2019. This rapid evolution poses challenges for vaccines and treatments designed to target the virus. A booster shot is now needed ...
Apr 16, 2022
0
4
An international research team discovered the first human antibody to effectively neutralize two types of hantaviruses in animal models, according to a study published online Mar. 16 in Science Translational Medicine. Based ...
Mar 21, 2022
0
47
Researchers at La Jolla Institute for Immunology (LJI) are designing better therapies for treating Ebola virus and its deadly relatives.
Mar 17, 2022
0
65
Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines. In the current study published in the journal mBIO, researchers at Baylor College ...
Feb 15, 2022
0
131
U.S. health regulators on Friday authorized a new antibody drug that targets the omicron variant, a key step in restocking the nation's arsenal against the latest version of COVID-19.
Feb 11, 2022
0
5
Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, ...
Jan 21, 2022
2
146
Researchers at UBC's faculty of medicine have conducted the world's first molecular-level structural analysis of the Omicron variant spike protein. The findings were published today in Science.
Jan 20, 2022
1
236
US biotech firm Regeneron said Tuesday that its synthetic antibody treatment for COVID-19 may be less effective against the new variant, and it plans to conduct tests to determine by how much.
Nov 30, 2021
0
4
A synthetic antibody treatment developed by Regeneron reduced the risk of developing symptomatic COVID by more than 80 percent up to eight months after receiving the treatment, the US biotech firm said Monday.
Nov 8, 2021
0
9
